Woodline Partners LP Takes $2.59 Million Position in CeriBell (NASDAQ:CBLL)

Woodline Partners LP bought a new position in shares of CeriBell (NASDAQ:CBLL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 100,000 shares of the company's stock, valued at approximately $2,588,000. Woodline Partners LP owned approximately 0.28% of CeriBell as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Legal & General Group Plc acquired a new stake in CeriBell in the 4th quarter valued at $32,000. Summit Investment Advisors Inc. purchased a new stake in CeriBell during the 4th quarter worth approximately $33,000. Tower Research Capital LLC TRC purchased a new position in shares of CeriBell in the fourth quarter valued at approximately $37,000. BNP Paribas Financial Markets purchased a new stake in shares of CeriBell during the fourth quarter worth approximately $43,000. Finally, PNC Financial Services Group Inc. acquired a new stake in CeriBell during the 4th quarter worth $47,000.

Analysts Set New Price Targets

Several analysts recently issued reports on CBLL shares. LADENBURG THALM/SH SH assumed coverage on shares of CeriBell in a research note on Friday, April 4th. They set a "buy" rating and a $32.00 price objective for the company. Canaccord Genuity Group reissued a "buy" rating and set a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, CeriBell currently has an average rating of "Buy" and a consensus price target of $32.50.

Insider Activity

In other news, CEO Xingjuan Chao sold 5,700 shares of the company's stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $15.02, for a total transaction of $85,614.00. Following the sale, the chief executive officer now owns 746,451 shares of the company's stock, valued at approximately $11,211,694.02. This represents a 0.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 49,700 shares of company stock valued at $796,434. 20.10% of the stock is currently owned by company insiders.

CeriBell Stock Performance

Shares of NASDAQ:CBLL traded down $0.09 during mid-day trading on Wednesday, reaching $17.19. 472,884 shares of the company were exchanged, compared to its average volume of 280,700. CeriBell has a 1 year low of $10.01 and a 1 year high of $32.75. The firm's 50-day simple moving average is $17.00 and its 200 day simple moving average is $21.95.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. The firm had revenue of $20.49 million during the quarter, compared to analyst estimates of $19.30 million. Equities research analysts forecast that CeriBell will post -2.46 EPS for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.